All In Biotech

Drug Trial Radar · NCT07011719

Study of Casdatifan and Cabozantinib Versus Placebo and Cabozantinib in Patients With Advanced Clear Cell Renal Cell Carcinoma

A Randomized, Double-Blind, Active-Control, Multicenter Phase 3 Trial of Casdatifan and Cabozantinib Versus Placebo and Cabozantinib in Patients With Advanced Clear Cell Renal Cell Carcinoma

Last checked: Nov 19, 2026Latest source record: Nov 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 720 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

720

Planned (sponsor's estimate)

Start

Sep 8, 2025

Primary completion

Apr 2028

Study completion Dec 2030

Sponsor

Lead sponsor
Arcus Biosciences, Inc.Industry
Sponsor type
Industry
First posted
Jun 10, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of the study is to evaluate the progression-free survival (PFS) of casdatifan versus placebo when each is given in combination with cabozantinib for patients who received anti-PD-1 or anti-PD-L1 therapy as part of the most recent regimen (either adjuvant monotherapy or first-line in combination with anti-CTLA-4 or VEGFR-TKI), with no more than 1 prior regimen in the metastatic setting.

Conditions

  • Metastatic Clear Cell Renal Cell Carcinoma
  • Advanced Clear Cell Renal Cell Carcinoma

Interventions

  • CasdatifanDrug

    Administered as specified in the treatment arm

  • CabozantinibDrug

    Administered as specified in the treatment arm

  • PlaceboDrug

    Administered as specified in the treatment arm

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression-free Survival (PFS) as assessed by Blinded Independent Central Review (BICR) according to RECIST 1.1Time frame: up to approximately 33 months

Locations

191 sites in 17 countries. Site status is shown where the registry gives one.

  • Research Site

    Gilbert, Arizona · Recruiting

  • Research Site

    Goodyear, Arizona · Recruiting

  • Research Site

    Phoenix, Arizona · Recruiting

  • Research Site

    Duarte, California · Recruiting

  • Research Site

    Irvine, California · Recruiting

  • Research Site

    La Jolla, California · Recruiting

  • Research Site

    Los Angeles, California · Recruiting

  • Research Site

    Palo Alto, California · Recruiting

  • Research Site

    Sacramento, California · Recruiting

  • Research Site

    San Diego, California · Recruiting

  • Research Site

    Aurora, Colorado · Recruiting

  • Research Site

    New Haven, Connecticut · Recruiting

  • Research Site

    Washington D.C., District of Columbia · Recruiting

  • Research Site

    Jacksonville, Florida · Recruiting

  • Research Site

    Miami, Florida · Recruiting

  • Research Site

    Orlando, Florida · Recruiting

  • Research Site

    Atlanta, Georgia · Recruiting

  • Research Site

    Atlanta, Georgia · Recruiting

  • Research Site

    Newnan, Georgia · Recruiting

  • Research Site

    Zion, Illinois · Recruiting

  • Research Site

    Indianapolis, Indiana · Recruiting

  • Research Site

    Louisville, Kentucky · Recruiting

  • Research Site

    Jefferson, Louisiana · Recruiting

  • Research Site

    Baltimore, Maryland · Recruiting

  • Research Site

    Boston, Massachusetts · Recruiting

  • Research Site

    Boston, Massachusetts · Recruiting

  • Research Site

    Rochester, Minnesota · Recruiting

  • Research Site

    St Louis, Missouri · Recruiting

  • Research Site

    Omaha, Nebraska · Recruiting

  • Research Site

    New Brunswick, New Jersey · Recruiting

  • Research Site

    Buffalo, New York · Recruiting

  • Research Site

    New York, New York · Recruiting

  • Research Site

    Rochester, New York · Recruiting

  • Research Site

    Chapel Hill, North Carolina · Recruiting

  • Research Site

    Durham, North Carolina · Recruiting

  • Research Site

    Cleveland, Ohio · Recruiting

  • Research Site

    Portland, Oregon · Recruiting

  • Research Site

    Monroeville, Pennsylvania · Recruiting

  • Research Site

    Charleston, South Carolina · Recruiting

  • Research Site

    Nashville, Tennessee · Recruiting

Showing 40 of 191 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.